皮肤鳞状细胞癌生物治疗进展
Biotherapy for cutaneous squamous cell carcinoma
吉祥 1王大光1
作者信息
- 1. 南京医科大学第一附属医院皮肤科,南京 210029
- 折叠
摘要
自2018年cemiplimab经美国食品药品管理局批准上市以来,抗程序性细胞死亡受体1抗体逐渐成为晚期皮肤鳞状细胞癌患者系统用药的一线选择.本文综述了目前皮肤鳞状细胞癌靶向治疗、免疫治疗、靶向/免疫联合治疗和基因治疗相关药物的临床应用.
Abstract
Since cemiplimab was approved by United States Food and Drug Administration in 2018,anti-programmed cell death receptor-1 antibodies have been considered as the first-line systemic therapy for advanced cutaneous squamous cell carcinoma.This review focuses on current clinical application of targeted therapy,immunotherapy,targeted immunotherapy and gene therapy for cutaneous squamous cell carcinoma.
关键词
癌,鳞状细胞/皮肤/分子靶向治疗/免疫疗法/生物治疗Key words
Carcinoma,squamous cell/Skin/Molecular targeted therapy/Immunotherapy/Biotherapy引用本文复制引用
出版年
2025
NETL
NSTL
万方数据